Opsis_logo_color.png

Press Releases

February 27, 2025 - BlueRock Therapeutics receives FDA Fast Track Designation for OpCT-001 for the treatment of primary photoreceptor diseases

September 03, 2024 - BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases

January 23, 2024 - BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics

August 31, 2022 - First U.S. patient receives autologous stem cell therapy to treat dry AMD

May 17, 2021 - BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases

About Opsis

Opsis Therapeutics is a company focused on advancing the pipeline of cell replacement therapies targeting ocular diseases. Leveraging innovations in induced pluripotent cell (iPSC) generation, retinal cell differentiation, and functional biomaterials, Opsis Therapeutics is developing cell therapies for patients with dry age-related macular degeneration (AMD), inherited macular degenerations (IMDs) and inherited retinal diseases (IRDs). Founded in 2016, Opsis Therapeutics is a joint venture of FUJIFILM Cellular Dynamics and David Gamm, M.D., Ph.D., and is headquartered in Madison, Wisconsin.

Privacy PolicyTerms of Use

  • Our Founders
  • Scientific Advisory Board